Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Greenfire Resources Ltd.’s GFR share price has dipped by 5.70%, which has investors questioning if this is right time to buy.

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

The following is a summary of “Associations between intercurrent events and cardiorenal clinical outcomes in non-diabetic ...

Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ...

AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

YAP, a protein known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, highlighting the importance of mimicking tumour ...

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...